Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending ...

Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments ...

Novo Nordisk beëindigde maandag een kortstondige overeenkomst om het afslankmiddel Wegovy via Hims & Hers Health te verkopen, ...

Novo Nordisk beëindigde maandag een kortstondige overeenkomst om het afslankmiddel Wegovy via Hims & Hers Health te verkopen.

The companies had announced a collaboration in April for Hims & Hers to sell Novo's Wegovy through an offering on the telehealth company's platform.

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

Investing.com - Deutsche Bank (ETR: DBKGn) handhaaft zijn Hold-advies en koersdoel van $ 43,00 voor het aandeel Hims & Hers (NYSE: HIMS) na de beëindiging van de samenwerking door Novo Nordisk (NYSE: ...

PLAINSBORO, N.J. - Novo Nordisk heeft de samenwerking met telehealth-aanbieder Hims & Hers Health, Inc. beëindigd, waardoor het bedrijf geen directe toegang meer heeft tot Wegovy via NovoCare Pharmacy ...

Novo Nordisk has announced it is ending its distribution collaboration with US telehealth firm Hims & Hers Health over the ...

Novo Nordisk ends Wegovy deal with Hims over legal issues, sending the stock tumbling. What happens next? Here's a look.